Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.

European journal of drug metabolism and pharmacokinetics - 1 Dec 2018

Uno Takaya, Wada Kyoichi, Matsuda Sachi, Terada Yuka, Oita Akira, Kawase Atsushi, Takada Mitsutaka

Abstract excerpt

BACKGROUND AND OBJECTIVE: Tacrolimus, a major immunosuppressant used after transplantation, is associated with large interindividual variation involving genetic polymorphisms in metabolic processes. A common variant of the cytochrome P450 (CYP) 3A5 gene, CYP3A5*3, affects blood concentrations of tacrolimus. However, tacrolimus pharmacokinetics at the early stage of transplantation have not been adequately studied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Gene Expression

Share to Heart Transplantation

Share to Immunosuppressive Agents

Share to Polymorphism, Genetic

Share to Tacrolimus

Source

Identifiers

PMID: 29691732
DOI: 10.1007/s13318-018-0478-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.PMID 29691732Read ↗

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.Semantic proximity Read ↗

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.Semantic proximity Read ↗

Impact of the <i>CYP3A4*1G</i> Polymorphism and its Combination with <i>CYP3A5</i> Genotypes on Tacrolimus Pharmacokinetics in Renal Transplant PatientsSemantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.Semantic proximity Read ↗

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.Semantic proximity Read ↗

Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.Semantic proximity Read ↗

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantationSemantic proximity Read ↗

Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.